SB
IBB icon

Strategic Blueprint’s iShares Biotechnology ETF IBB Stock Holding History

Strategic Blueprint’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
6,775
+336
+5% +$57.8K 0.06% 270
2026
Q1 		$1.09M Buy
+6,439
New +$1.1M 0.06% 268
2021
Q3 		– Sell
-150
Closed -$25K – 818
2021
Q2 		$25K Buy
+150
New +$23.1K ﹤0.01% 769
2019
Q4 		– Sell
-150
Closed -$15K – 233
2019
Q3 		$15K Buy
+150
New +$15.7K 0.01% 258

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Strategic Blueprint's IBB Position: Q2 2026 in Review

Strategic Blueprint increased its iShares Biotechnology ETF (IBB) stake by 5.2% in Q2 2026, buying an estimated $57.8K and bringing the position to 6,775 shares worth $1.29M. The position accounts for 0.06% of the portfolio, ranked #270.

Strategic Blueprint first reported a position in IBB in Q3 2019 and has held it in 4 quarters since. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Strategic Blueprint held 6,775 shares of iShares Biotechnology ETF worth $1.29M as of Q2 2026.
  • Strategic Blueprint bought 336 iShares Biotechnology ETF shares in Q2 2026, an estimated $57.8K.
  • iShares Biotechnology ETF made up 0.06% of Strategic Blueprint's portfolio in Q2 2026, its #270 holding.
  • Strategic Blueprint first reported a position in iShares Biotechnology ETF in Q3 2019 and has held it in 4 quarters since.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Strategic Blueprint's 13F filing for Q2 2026, filed 23 Jul 2026.